P461New targets of therapy at rheumatoid vasculitis: focus on microcirculation

The rheumatoid vaskulitis (RV) strikes about a quarter of patients with rheumatoid arthritis, causing defeat of visceral bodies and systems, a cachexy and progressing of articulate destruction. Therefore RV treatment - an actual problem of modern rheumatology. Aim: To study microcirculation at sick RV and possibility of its improvement the pentoxifyllini. Materials and methods: Research included women, patients rheumatoid artritis (n=69). Middle age - 55,54±3,22 years. Having positive antibodies to cyclic citrullined peptide (ACCP) and a positive rheumatoid factor in blood. All patients received DMARD-therapy. Microcirculation was investigated by a method of a laser Doppler flowmetri on forearm skin. Two groups of patients - intact (n=39), not receiving a preparation and research (n=30), receiving a preparation are allocated. Pentoxifyllin was entered in an average dose of 800 milligrams per day.Research was conducted within two weeks. Statistical processing carried out by means of Mann-Whitney methods. Results: Microcirculation in the first group made 14,28±5,21 perfusion units. In the second group - 19,24±2,65 perfusion units that made statistically significant difference (p=0,00032). Clinically patients of intact group had no dynamics. The patients receiving in addition to DMARD therapy pentoxifyllin (the second group) had positive clinical dynamics of articulate and visceral syndromes. Moreover, statistically significantly lower CRP levels (p=0,0043). Conclusion: Pentoxifyllin inclusion in a dose of 800 mg per day leads to positive clinical and laboratory dynamics at patients rheumatoid vaskulitis and can be a new target for therapy.